298 related articles for article (PubMed ID: 23909948)
1. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells.
Wu Q; Xu W; Cao L; Li X; He T; Wu Z; Li W
J Proteome Res; 2013 Sep; 12(9):4064-73. PubMed ID: 23909948
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Wu Q; Cheng Z; Zhu J; Xu W; Peng X; Chen C; Li W; Wang F; Cao L; Yi X; Wu Z; Li J; Fan P
Sci Rep; 2015 Mar; 5():9520. PubMed ID: 25825284
[TBL] [Abstract][Full Text] [Related]
3. SAHA regulates histone acetylation, Butyrylation, and protein expression in neuroblastoma.
Xu G; Wang J; Wu Z; Qian L; Dai L; Wan X; Tan M; Zhao Y; Wu Y
J Proteome Res; 2014 Oct; 13(10):4211-9. PubMed ID: 25160476
[TBL] [Abstract][Full Text] [Related]
4. Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome.
Wang TY; Jia YL; Zhang X; Sun QL; Li YC; Zhang JH; Zhao CP; Wang XY; Wang L
Sci Rep; 2015 Dec; 5():18443. PubMed ID: 26675280
[TBL] [Abstract][Full Text] [Related]
5. Ultradeep Lysine Crotonylome Reveals the Crotonylation Enhancement on Both Histones and Nonhistone Proteins by SAHA Treatment.
Wu Q; Li W; Wang C; Fan P; Cao L; Wu Z; Wang F
J Proteome Res; 2017 Oct; 16(10):3664-3671. PubMed ID: 28882038
[TBL] [Abstract][Full Text] [Related]
6. Global Analysis of Lysine 2-Hydroxyisobutyrylome upon SAHA Treatment and Its Relationship with Acetylation and Crotonylation.
Wu Q; Ke L; Wang C; Fan P; Wu Z; Xu X
J Proteome Res; 2018 Sep; 17(9):3176-3183. PubMed ID: 30109935
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
8. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 Cells.
Zhu X; Liu X; Cheng Z; Zhu J; Xu L; Wang F; Qi W; Yan J; Liu N; Sun Z; Liu H; Peng X; Hao Y; Zheng N; Wu Q
Sci Rep; 2016 Jan; 6():19926. PubMed ID: 26822725
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
11. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
12. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
[TBL] [Abstract][Full Text] [Related]
13. Lysine acetylation targets protein complexes and co-regulates major cellular functions.
Choudhary C; Kumar C; Gnad F; Nielsen ML; Rehman M; Walther TC; Olsen JV; Mann M
Science; 2009 Aug; 325(5942):834-40. PubMed ID: 19608861
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
15. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation.
Ge Y; Gong Z; Olson JR; Xu P; Buck MJ; Ren X
Toxicology; 2013 Oct; 312():30-5. PubMed ID: 23891734
[TBL] [Abstract][Full Text] [Related]
19. Quantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass Spectrometry.
Krautkramer KA; Reiter L; Denu JM; Dowell JA
J Proteome Res; 2015 Aug; 14(8):3252-62. PubMed ID: 26120868
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
